The effect of atorvastatin and its role on systemic cytokine network in treatment of acute experimental colitis

Inflammatory bowel diseases are characterized by disabilities in gastrointestinal system and defects in mucosal immune system. Statins are 3-hydroxy-3-methyl glutaryl coenzyme A reductase inhibitor and are used to treat hypercholesterolemia in patients with coronary artery and atherosclerotic diseases. Recent studies have demonstrated that statins have immunomodulatory role by effecting different pathways in immune system. In this study, we investigated the effect of atorvastatin and its mechanism on systemic immune response in treatment of trinitrobenzene sulfonic acid (TNBS)-induced colitis mice. We observed that atorvastatin significantly suppressed the severity of TNBS-induced colitis in BALB/c mice. This was manifested in reduced rectal bleeding, decrease in colon length, reduction of histological damage, and improved survival. Concurrently, we investigated the immunomodulatory role of atorvastatin on systemic immune system. We investigated the proinflammatory (IL-1 alpha, IL-6, TNF-alpha), Th1 (IFN-gamma, IL-2), Th2 (IL-4, IL-5, IL-10), and Th17 (IL-17, IL-23) cytokine levels in serum samples of colitis and atorvastatin-administered mice. We discovered that administration of atorvastatin significantly down-regulates systemic TNF-a level and Th17 cytokine levels. Furthermore, atorvastatin treatment switches Th1 type T-cell response toward/to Th2 (IL-4, IL-10) type response.

Yazar Aktunc, Erol
Kayhan, Basak
Arasli, Mehmet
Gun, Banu Dogan
Barut, Figen
Yayın Türü Article
Tek Biçim Adres https://hdl.handle.net/20.500.12628/3488
Tek Biçim Adres 10.3109/08923973.2011.559475
Konu Başlıkları Inflammatory bowel diseases
statin
systemic immune response
Th1
Th2
Th17
cytokines
Koleksiyonlar Araştırma Çıktıları | WoS | Scopus | TR-Dizin | PubMed | SOBİAD
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu
Dergi Adı IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
Dergi Cilt Bilgisi 33
Dergi Sayısı 4
Sayfalar 667 - 675
Yayın Yılı 2011
Eser Adı
[dc.title]
The effect of atorvastatin and its role on systemic cytokine network in treatment of acute experimental colitis
Yazar
[dc.contributor.author]
Aktunc, Erol
Yazar
[dc.contributor.author]
Kayhan, Basak
Yazar
[dc.contributor.author]
Arasli, Mehmet
Yazar
[dc.contributor.author]
Gun, Banu Dogan
Yazar
[dc.contributor.author]
Barut, Figen
Yayın Yılı
[dc.date.issued]
2011
Yayıncı
[dc.publisher]
INFORMA HEALTHCARE
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
Inflammatory bowel diseases are characterized by disabilities in gastrointestinal system and defects in mucosal immune system. Statins are 3-hydroxy-3-methyl glutaryl coenzyme A reductase inhibitor and are used to treat hypercholesterolemia in patients with coronary artery and atherosclerotic diseases. Recent studies have demonstrated that statins have immunomodulatory role by effecting different pathways in immune system. In this study, we investigated the effect of atorvastatin and its mechanism on systemic immune response in treatment of trinitrobenzene sulfonic acid (TNBS)-induced colitis mice. We observed that atorvastatin significantly suppressed the severity of TNBS-induced colitis in BALB/c mice. This was manifested in reduced rectal bleeding, decrease in colon length, reduction of histological damage, and improved survival. Concurrently, we investigated the immunomodulatory role of atorvastatin on systemic immune system. We investigated the proinflammatory (IL-1 alpha, IL-6, TNF-alpha), Th1 (IFN-gamma, IL-2), Th2 (IL-4, IL-5, IL-10), and Th17 (IL-17, IL-23) cytokine levels in serum samples of colitis and atorvastatin-administered mice. We discovered that administration of atorvastatin significantly down-regulates systemic TNF-a level and Th17 cytokine levels. Furthermore, atorvastatin treatment switches Th1 type T-cell response toward/to Th2 (IL-4, IL-10) type response.
Açıklama
[dc.description]
WOS: 000296643200014
Açıklama
[dc.description]
PubMed: 21428710
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
eng
Konu Başlıkları
[dc.subject]
Inflammatory bowel diseases
Konu Başlıkları
[dc.subject]
statin
Konu Başlıkları
[dc.subject]
systemic immune response
Konu Başlıkları
[dc.subject]
Th1
Konu Başlıkları
[dc.subject]
Th2
Konu Başlıkları
[dc.subject]
Th17
Konu Başlıkları
[dc.subject]
cytokines
Haklar
[dc.rights]
info:eu-repo/semantics/closedAccess
ISSN
[dc.identifier.issn]
0892-3973
İlk Sayfa Sayısı
[dc.identifier.startpage]
667
Son Sayfa Sayısı
[dc.identifier.endpage]
675
Dergi Adı
[dc.relation.journal]
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
Dergi Sayısı
[dc.identifier.issue]
4
Dergi Cilt Bilgisi
[dc.identifier.volume]
33
Tek Biçim Adres
[dc.identifier.uri]
https://dx.doi.org/10.3109/08923973.2011.559475
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/3488
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
27
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
07 Nisan 2024 15:57
Google Kontrol
Tıklayınız
atorvastatin system immune systemic response colitis investigated significantly IL-10) treatment cytokine levels diseases immunomodulatory reduced survival decrease improved damage rectal reduction length bleeding histological Inflammatory Concurrently samples toward/to T-cell switches Furthermore down-regulates administration discovered atorvastatin-administered
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms